Why the study?
Gene therapies increasing SMN are not effective for all SMA patients, prompting investigation into UPR status and whether UPR modulation offers therapeutic benefit.
Does IRE1α/XBP1 pathway restoration improve SMN expression and motor neuron survival in SMA models?
Does IRE1α/XBP1 pathway restoration improve SMN expression and motor neuron survival in SMA models?
Restoring the IRE1α-XBP1 pathway by overexpressing XBP1s enhances SMN expression and promotes motor neuron survival in preclinical models of spinal muscular atrophy.
ATF6 activation may enhance MN survival in SMA; leaves open adjunctive UPR modulation beyond gene therapy.
AIM: Spinal muscular atrophy (SMA) is a neuromuscular disease caused by survival of motor neuron (SMN) deficiency that induces motor neuron (MN) degeneration and severe muscular atrophy. Gene therapies that increase SMN have proven their efficacy but not for all patients. Here, we explored the unfolded protein response (UPR) status in SMA pathology and explored whether UPR modulation could be beneficial for SMA patients. METHODS: We analysed the expression and activation of key UPR proteins by RT-qPCR and by western blots in SMA patient iPSC-derived MNs and one SMA cell line in which SMN expression was re-established (rescue). We complemented this approach by using myoblast and fibroblast SMA patient cells and SMA mouse models of varying severities. Finally, we tested in vitro and in vivo the effect of IRE1α/XBP1 pathway restoration on SMN expression and subsequent neuroprotection. RESULTS: We report that the IRE1α/XBP1 branch of the unfolded protein response is disrupted in SMA, with a depletion of XBP1s irrespective of IRE1α activation pattern. The overexpression of XBP1s in SMA fibroblasts proved to transcriptionally enhance SMN expression. Importantly, rebalancing XBP1s expression in severe SMA-like mice, induced SMN expression and spinal MN protection. CONCLUSIONS: We have identified XBP1s depletion as a contributing factor in SMA pathogenesis, and the modulation of this transcription factor proves to be a plausible therapeutic avenue in the context of pharmacological interventions for patients.
No takes yet. Share an insight, caveat, or question.
D’Amico et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: